Shanghai Sonyt Biotechnology Co., Ltd. is one of the leading manufacturers and suppliers of ffagldd tfa in China, also supports custom service. Welcome to wholesale bulk high quality ffagldd tfa from our factory. Contact us for more details.
| Description | FFAGLDD (TFA salt form) is a 7-amino-acid peptide with the sequence Phe-Phe-Ala-Gly-Leu-Asp-Asp (FFAGLDD), a matrix metalloproteinase 9 (MMP9, also known as gelatinase B) selective cleavage peptide. MMP9 is a zinc-dependent endopeptidase that is highly expressed in the tumor microenvironment, inflammatory sites, and tissue remodeling processes, participating in extracellular matrix degradation, tumor invasion and metastasis, angiogenesis, and other pathological processes. The FFAGLDD sequence contains a specific motif recognized and cleaved by MMP9, which can be cleaved by MMP9 at a specific site, thereby achieving enzyme-responsive controlled drug release. Design features of FFAGLDD: (1) N-terminal diphenylalanine (Phe-Phe) - provides hydrophobicity, can bind to the hydrophobic pockets (S1', S2' pockets) of the MMP9 active site, and is a key element for MMP9 recognition; (2) intermediate alanine-glycine-leucine (Ala-Gly-Leu) - constitutes the core sequence of the MMP9 cleavage site, glycine (Gly) provides conformational flexibility, leucine (Leu) occupies the S1 pocket of MMP9; (3) C-terminal diaspartic acid (Asp-Asp) - provides negative charge, regulates peptide solubility and electrostatic interactions with the MMP9 active site, while aspartic acid residues may participate in coordination with the catalytic zinc ion of MMP9. Applications of FFAGLDD include: (1) tumor-targeted drug delivery - as an enzyme-responsive linker connecting chemotherapeutic drugs (such as doxorubicin DOX) to targeting ligands or nanocarriers, which are cleaved under conditions of high MMP9 expression in the tumor microenvironment, achieving spatiotemporally controlled drug release, increasing drug concentration at the tumor site, and reducing systemic toxicity; (2) prodrug design - conjugating drugs with FFAGLDD to form prodrugs, where active drugs are only cleaved and released at tumor sites with high MMP9 expression; (3) MMP9 activity detection - connecting fluorescent dyes and quenching groups to both ends of FFAGLDD respectively, constructing MMP9 activity fluorescent probes, where fluorescence is restored after MMP9 cleavage, used for real-time detection and imaging of MMP9 activity; (4) tumor imaging - after labeling with radionuclides or fluorescent dyes, used for imaging diagnosis of MMP9-high-expressing tumors; (5) hydrogel degradation regulation - introducing FFAGLDD into the hydrogel network to achieve MMP9-responsive hydrogel degradation and drug release. FFAGLDD is provided as a TFA salt, which improves the water solubility and stability of the peptide. FFAGLDD is an important tool peptide for developing MMP9-responsive drug delivery systems and tumor diagnostic and therapeutic strategies. |
Product Basic Information Table
| Product Standard English Name | Product Abbreviation / Alias | Function Tags (comma-separated) | Core Structure | Molecular Formula | Exact Mass (Da) | Average MW (Da) | Salt Form | Length (aa) |
| FFAGLDD TFA | FFAGLDD heptapeptide TFA salt; di-aspartic acid peptide | Protease inhibitor, enzyme binding probe, protein interaction study, acidic polypeptide | Linear heptapeptide Phe-Phe-Ala-Gly-Leu-Asp-Asp with diphenylalanine hydrophobic motif and di-aspartic acid anionic groups; serves as aspartic protease inhibitor lead and protein interaction probe | C₃₅H₄₆N₆O₁₁·xTFA | 730.32 (free peptide) | ~730.8 (free peptide) | Trifluoroacetate (TFA) | 7 |
Physicochemical Solubility & Storage Parameters
| Product Code | Appearance | Long-term Storage | Short-term Storage | Solution Stability | Solid Powder Stability |
| PEP-FFA07-T | White powder | Store at -20°C, sealed, dry and protected from light. Aliquot for storage. | Stable for 1 month at 2–8°C in sealed dry condition; stable for shipping at ambient temperature. | Stable for 7 days at 4°C. TFA salt is readily soluble in water, dilute acetic acid and alkaline buffers. Better solubility of di-aspartic acid peptide under alkaline conditions; carboxyl protonation and reduced solubility under strong acidic conditions. | Stable for 2 years at -20°C, dry and protected from light. |
Functional Description
| Product Code | Frontend Short Summary (for search list display) | Detailed Biological Function Description | Applicable Research Areas (comma-separated) | Targets / Pathways |
| PEP-FFA07-T | FFAGLDD acidic heptapeptide as aspartic protease inhibitor lead | FFAGLDD is an acidic heptapeptide containing two aspartic acids. The diphenylalanine hydrophobic motif binds to the hydrophobic pocket of target enzymes, and the di-aspartic acid side chains form electrostatic interactions with the enzyme active site. It serves as a lead molecule for aspartic protease (e.g. BACE1, cathepsin D) inhibitors. | Protease inhibitor development, enzymology & mechanism research, neurodegenerative disease research, protein interaction, drug lead optimization | Aspartic protease active site; enzyme substrate binding pocket; electrostatic & hydrophobic interactions |
Hot Tags: ffagldd tfa, China ffagldd tfa manufacturers, suppliers, factory, 191936-91-1, 651328-78-8, 997-20-6, CAS 997 20 6, drug delivery peptides, therapeutic and pharmaceutical peptides
